Literature DB >> 34209830

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.

Luca Aresu1, Laura Marconato2, Valeria Martini3, Antonella Fanelli1, Luca Licenziato1, Greta Foiani4, Erica Melchiotti4, Arturo Nicoletti1, Marta Vascellari4.   

Abstract

Immune checkpoints are a set of molecules dysregulated in several human and canine cancers and aberrations of the PD-1/PD-L1 axis are often correlated with a worse prognosis. To gain an insight into the role of immune checkpoints in canine diffuse large B-cell lymphoma (cDLBCL), we investigated PD-L1, PD-1 and CD8A expression by RNAscope. Results were correlated with several clinico-pathological features, including treatment, Ki67 index and outcome. A total of 33 dogs treated with chemotherapy (n = 12) or chemoimmunotherapy with APAVAC (n = 21) were included. PD-L1 signal was diffusely distributed among neoplastic cells, whereas PD-1 and CD8A were localized in tumor infiltrating lymphocytes. However, PD-1 mRNA was also retrieved in tumor cells. An association between PD-L1 and PD-1 scores was identified and a higher risk of relapse and lymphoma-related death was found in dogs treated with chemotherapy alone and dogs with higher PD-L1 and PD-1 scores. The correlation between PD-L1 and PD-1 is in line with the mechanism of immune checkpoints in cancers, where neoplastic cells overexpress PD-L1 that, in turn, binds PD-1 receptors in activated TIL. We also found that Ki67 index was significantly increased in dogs with the highest PD-L1 and PD-1 scores, indirectly suggesting a role in promoting tumor proliferation. Finally, even if the biological consequence of PD-1+ tumor cells is unknown, our findings suggest that PD-1 intrinsic expression in cDLBCL might contribute to tumor growth escaping adaptive immunity.

Entities:  

Keywords:  PD-1; PD-L1; RNAscope; diffuse large B-cell lymphoma; dog

Year:  2021        PMID: 34209830     DOI: 10.3390/vetsci8070120

Source DB:  PubMed          Journal:  Vet Sci        ISSN: 2306-7381


  39 in total

1.  Programmed Cell Death Ligand 1 Expression in Canine Cancer.

Authors:  Kazuha Shosu; Masashi Sakurai; Kumi Inoue; Takayuki Nakagawa; Hiroki Sakai; Masahiro Morimoto; Masaru Okuda; Shunsuke Noguchi; Takuya Mizuno
Journal:  In Vivo       Date:  2016 May-Jun       Impact factor: 2.155

2.  Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.

Authors:  Matthew J Cascio; Elizabeth M Whitley; Bikash Sahay; Galaxia Cortes-Hinojosa; Lung-Ji Chang; Jonathan Cowart; Marc Salute; Elias Sayour; Michael Dark; Zachary Sandoval; Duane A Mitchell; Rowan J Milner
Journal:  Vet Immunol Immunopathol       Date:  2020-12-15       Impact factor: 2.046

3.  Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.

Authors:  Valeria Martini; Luca Aresu; Fulvio Riondato; Laura Marconato; Marzia Cozzi; Damiano Stefanello; Stefano Comazzi
Journal:  Res Vet Sci       Date:  2019-06-11       Impact factor: 2.534

4.  Immune regulation of canine tumour and macrophage PD-L1 expression.

Authors:  G Hartley; E Faulhaber; A Caldwell; J Coy; J Kurihara; A Guth; D Regan; S Dow
Journal:  Vet Comp Oncol       Date:  2016-02-04       Impact factor: 2.613

Review 5.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

6.  Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.

Authors:  Naoya Maekawa; Satoru Konnai; Tomohiro Okagawa; Asami Nishimori; Ryoyo Ikebuchi; Yusuke Izumi; Satoshi Takagi; Yumiko Kagawa; Chie Nakajima; Yasuhiko Suzuki; Yukinari Kato; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

7.  Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers.

Authors:  Laura Marconato; Luca Aresu; Damiano Stefanello; Stefano Comazzi; Valeria Martini; Roberta Ferrari; Fulvio Riondato; Nicole Rouquet; Patrick Frayssinet; Silvia Sabattini
Journal:  J Immunother Cancer       Date:  2019-06-07       Impact factor: 13.751

Review 8.  A snapshot of the PD-1/PD-L1 pathway.

Authors:  Chinmoy Ghosh; Gary Luong; Yue Sun
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

9.  A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.

Authors:  Masaya Igase; Yuki Nemoto; Kazuhito Itamoto; Kenji Tani; Munekazu Nakaichi; Masashi Sakurai; Yusuke Sakai; Shunsuke Noguchi; Masahiro Kato; Toshihiro Tsukui; Takuya Mizuno
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

View more
  2 in total

1.  IL-1R8 Downregulation and Concomitant TLR7 and TLR9 Upregulation Are Related to the Pathogenesis of Canine Diffuse Large B-Cell Lymphoma.

Authors:  Federica Riva; Joel Filipe; Antonella Fanelli; Laura Marconato; Alessia Inglesi; Eugenio Scanziani; Sabina Soldati; Luca Licenziato; Stefano Comazzi; Lucia Minoli; Luca Aresu
Journal:  Vet Sci       Date:  2022-04-25

Review 2.  The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology.

Authors:  Sandra Schöniger; Bharat Jasani
Journal:  Animals (Basel)       Date:  2022-10-04       Impact factor: 3.231

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.